Tumor Mutation Burden-Related Histopathologic Features for Predicting Overall Survival in Gliomas Using Graph Deep Learning.

Journal: The American journal of pathology
PMID:

Abstract

Tumor mutation burden (TMB) is a potential biomarker for evaluating the prognosis and response to immune checkpoint inhibitors, but its costly and time-consuming method of measurement limits its widespread application. This study aimed to identify the TMB-related histopathologic features from hematoxylin and eosin slides and explore their prognostic value in gliomas. TMB-related features were detected using a graph convolutional neural network from whole-slide images of patients from The Cancer Genome Atlas data set (619 patients), and the correlation between features and TMB was evaluated in an external validation set (237 patients). TMB-related features were used for predicting overall survival (OS) of patients to investigate whether these features have potential for prognostic prediction. Moreover, biological pathways underlying the prognostic value of the features were further explored. Histopathologic features derived from whole-slide images were significantly associated with patient TMB (P = 0.007 in the external validation set). TMB-related features showed excellent performance for OS prediction, and patients with lower-grade gliomas could be further stratified into different risk groups according to the features (P = 0.00013; hazard ratio, 4.004). Pathways involved in the cell cycle and execution of immune response were enriched in patients with higher OS risk. The TMB-related features could be used to estimate TMB and aid in prognostic risk stratification of patients with glioma with dysregulated biological pathways.

Authors

  • Caixia Sun
    CAS Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing, China; Beijing Advanced Innovation Centre for Big Data-Based Precision Medicine, School of Medicine and Engineering, Beihang University, Beijing, China; Key Laboratory of Big Data-Based Precision Medicine, Ministry of Industry and Information Technology, Beihang University, Beijing, China.
  • Tao Luo
  • Zhenyu Liu
    School of Electronic Information, Hangzhou Dianzi University, Hangzhou 310018, China.
  • Jia Ge
    Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University) and Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Chongqing.
  • Lizhi Shao
    CAS Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing, China; School of Computer Science and Engineering, Southeast University, Nanjing, China.
  • Xiangyu Liu
    School of Pharmacy, Shenyang Medical College, Shenyang 110034, People's Republic of China.
  • Bao Li
    Key Laboratory of Cardiovascular Diseases, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
  • Song Zhang
    College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
  • Qi Qiu
    CAS Key Laboratory of Molecular Imaging, Institute of Automation, Beijing, China.
  • Wei Wei
    Dept. Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, USA.
  • Shuo Wang
    College of Tea & Food Science, Anhui Agricultural University, Hefei, China.
  • Xiu-Wu Bian
    Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University) and Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Chongqing. Electronic address: bianxiuwu@263.net.
  • Jie Tian
    CAS Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing 100190, China.